Farma

Innovative ingredient sourcing in line with production safety requirements

Constant search for ingredients and active ingredients which make the company more competitive in the market. Interest in sustainably sourced alternative compounds that respect safety requirements.

To verify compound performance using techniques alternative to animal studies, guaranteeing that the expected effect is developed.

At AINIA we give you value



  • Obtaining active ingredients (APIs) by Supercritical Fluid Extraction (SFX)

  • Designing biofactories to obtain molecules with novel functionalities, active pharmaceutical ingredients

  • Development of microencapsulation systems to deliver the APIs.

  • Functionality studies with in vitro models. More biorelevant preclinical data to achieve safer screening of candidates. This reduces the number of candidates and, consequently, the time and cost of drug development.


Development of active pharmaceutical ingredients

 

Development of active pharmaceutical ingredients using supercritical fluids. In one single extraction and purification step, we extract high concentrations of the active ingredient with high purity. These processes are clean. They leave no waste or pollutants, so there is no need to manage waste or by-products.

On the other hand, we design biosynthesis processes starting with the selection of microorganisms for the industrial production of active ingredients with functional activity. Biofactories are also used to obtain molecules such as active pharmaceutical ingredients. We have our own collection of more than 400 natural strains with various functionalities.

We design microencapsulation processes to guarantee the protection and controlled release of the active ingredients. This ensures that they develop the intended biological activity.

We have a comprehensive in vitro model that is able to study the release and absorption of active ingredients for formulation into pharmaceuticals. Thus, we are able to obtain more biorelevant preclinical data than with standardised analytical methods.

We have a platform to assess intestinal permeability and absorption of bioactive ingredients (APIs). We use an intestinal epithelial cell model to reproduce intestinal absorption dynamically. We employ organ-on-chip technology, based on the use of microfluidic platforms to faithfully reproduce an intestine on a chip.

We complement this dynamic cellular platform with our in vitro models to simulate gastrointestinal digestion for pharmacopoeia. This enables us to improve and optimise the formulation and development of new galenic formulations. We faithfully simulate oral, gastric and intestinal digestion (small intestine and intestinal microbiota of the colon) to study the resistance and absorption of bioactive compounds, as well as for drug dissolution studies.

How can I help you?

I have read and accept the privacy policy.

I agree to receive notifications from AINIA

Begoña Ruiz
Head of Biotechnology Department

Subscribe to our newsletter

Sign-up to get the latest news straight to your inbox.
ENVIAR
Give it a try, you can unsubscribe anytime.